BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 van den Bosch BJ, Coenen MJ. Pharmacogenetics of inflammatory bowel disease. Pharmacogenomics 2021;22:55-66. [PMID: 33305616 DOI: 10.2217/pgs-2020-0095] [Reference Citation Analysis]
2 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Reference Citation Analysis]
3 Pinton P. Combination of vedolizumab and immunomodulators in ulcerative colitis. J Gastroenterol Hepatol 2021;36:3556. [PMID: 34519096 DOI: 10.1111/jgh.15686] [Reference Citation Analysis]
4 Wang W, Xu C, Li X, Wang Z, Yang J, Shen Y, Shi M, Chen L, Zhang L, Guo Y, Wang B, Zhang T, Pu Y. Exploration of the potential mechanism of Banxia Xiexin Decoction for the effects on TNBS-induced ulcerative colitis rats with the assistance of network pharmacology analysis. J Ethnopharmacol 2021;277:114197. [PMID: 34004261 DOI: 10.1016/j.jep.2021.114197] [Reference Citation Analysis]
5 LeBlanc JF, Segal JP, de Campos Braz LM, Hart AL. The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis. Nutrients 2021;13:1780. [PMID: 34071065 DOI: 10.3390/nu13061780] [Reference Citation Analysis]
6 Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, Cohen BL, Ungaro RC, Harlan W, Hanson J, Konijeti G, Polyak S, Ritter T, Salzberg B, Seminerio J, English E, Zhang X, Sharma PP, Herfarth HH. Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflamm Bowel Dis 2022:izac121. [PMID: 35700276 DOI: 10.1093/ibd/izac121] [Reference Citation Analysis]
7 Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther 2020;52:481-91. [PMID: 32573825 DOI: 10.1111/apt.15876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Liu L, Liu Q, Chang J, Dong X, Ma W. Cell division control 42 elevates during infliximab therapy, and its increment relates to treatment response in ulcerative colitis patients. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24477] [Reference Citation Analysis]
9 Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00210-X. [PMID: 33640480 DOI: 10.1016/j.cgh.2021.02.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
10 Zhuo LL, Zhuge WW, Ding YR. Impact of TTM-oriented health promotion and education method based on WeChat platform on positive emotions, negative emotions, and self-care ability of patients with ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2021; 29(19): 1144-1150 [DOI: 10.11569/wcjd.v29.i19.1144] [Reference Citation Analysis]
11 Ahmed W, Galati J, Kumar A, Christos PJ, Longman R, Lukin DJ, Scherl E, Battat R. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00344-X. [PMID: 33798711 DOI: 10.1016/j.cgh.2021.03.034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
12 Yzet C, Diouf M, Singh S, Brazier F, Turpin J, Nguyen-khac E, Meynier J, Fumery M. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis. Clinical Gastroenterology and Hepatology 2021;19:668-679.e8. [DOI: 10.1016/j.cgh.2020.06.071] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
13 Ho EY, Singh S, Terdiman JP. Providing the Best Care for Patients With Crohn's Disease: An Examination of the New AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2557-62. [PMID: 34051986 DOI: 10.1053/j.gastro.2021.04.024] [Reference Citation Analysis]
14 Gordon M, Sinopoulou V, Grafton-Clarke C, Akobeng AK. Antibiotics for the induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2022;5:CD013743. [PMID: 35583095 DOI: 10.1002/14651858.CD013743.pub2] [Reference Citation Analysis]
15 Ahuja D, Singh S. Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice. Curr Opin Gastroenterol 2022;38:337-46. [PMID: 35762693 DOI: 10.1097/MOG.0000000000000854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kim M, Jeon J. Recent Advances in Understanding Nrf2 Agonism and Its Potential Clinical Application to Metabolic and Inflammatory Diseases. IJMS 2022;23:2846. [DOI: 10.3390/ijms23052846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Hellström PM, Gemmen E, Ward HA, Koo H, Faccin F, Xue Z, Malmborg P. Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study. Scand J Gastroenterol 2022;:1-8. [PMID: 35833832 DOI: 10.1080/00365521.2022.2090275] [Reference Citation Analysis]
18 Holmer AK, Singh S. Expanding targeted immune modulators in ulcerative colitis. Lancet 2021;397:2313-5. [PMID: 34090626 DOI: 10.1016/S0140-6736(21)00891-6] [Reference Citation Analysis]
19 Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis 2021;15:950-9. [PMID: 33475734 DOI: 10.1093/ecco-jcc/jjab016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
21 Guan F, Luo H, Wu J, Li M, Chen L, Huang N, Wei G, Nie J, Chen B, Su Z, Zhang X, Liu Y. Andrographolide sodium bisulfite ameliorates dextran sulfate sodium-induced colitis and liver injury in mice via inhibiting macrophage proinflammatory polarization from the gut-liver axis. Int Immunopharmacol 2022;110:109007. [PMID: 35779489 DOI: 10.1016/j.intimp.2022.109007] [Reference Citation Analysis]
22 Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therap Adv Gastroenterol 2021;14:17562848211021760. [PMID: 34262610 DOI: 10.1177/17562848211021760] [Reference Citation Analysis]
23 Xu D, Zhang H, Chen Y. Patients' views of shared decision making in inflammatory bowel disease: a survey in China. BMC Med Inform Decis Mak 2021;21:340. [PMID: 34872536 DOI: 10.1186/s12911-021-01702-8] [Reference Citation Analysis]
24 Ahmed W, Scott FI. Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00564-4. [PMID: 34022455 DOI: 10.1016/j.cgh.2021.05.026] [Reference Citation Analysis]
25 Singh S. Reply. Clin Gastroenterol Hepatol 2021;19:2221. [PMID: 33279781 DOI: 10.1016/j.cgh.2020.11.036] [Reference Citation Analysis]
26 Abraham B, Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol 2021;37:344-50. [PMID: 33731642 DOI: 10.1097/MOG.0000000000000738] [Reference Citation Analysis]
27 Gordon M, Grafton-clarke C, Sinopoulou V, Akobeng AK; Cochrane Gut Group. Antibiotics for the induction and maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013743] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]